Search

Investigators have shown how gut microbes promote the formation of a type of immune cell called regulatory T cells.

… Wednesday, April 22, 2020 Summary An MSK team has learned how gut microbes promote the formation of a type of immune cell called regulatory T cells. The research could improve scientists’ understanding of conditions like inflammatory bowel disease. The microscopic organisms that live in our intestines

Learn how new clinical trials at MSK are helping make cancer care at home a reality.

… Monday, June 3, 2024 Robert Daly, MD, MBA, a thoracic oncologist at Memorial Sloan Kettering, presented important new research about delivering high quality cancer care at home during the 2024 ASCO conference, the nation’s premier cancer conference. This research focuses on incorporating telemedicine

VEXAS syndrome is a confounding adult-onset inflammatory disease first described in 2020, which affects 1 in 4,000 men over 50. Now, MSK researchers are shedding new light on its mechanisms and laying the groundwork for potential targeted treatments.

… Monday, November 3, 2025 Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed some of the first robust laboratory models of a confounding adult-onset inflammatory disease called VEXAS syndrome — shedding new light on its mechanisms and laying the groundwork for potential targeted

Inheriting a mutation in the CDH1 gene can raise risk of a rare stomach cancer called hereditary diffuse gastric cancer.

… Thursday, July 22, 2021 Stomach (gastric) cancer is the third leading cause of cancer deaths in the world today. About 10% of these cancers are due to a genetic mutation inherited from a parent. One specific mutation, called CDH1 , puts a person at very high risk for a rare but lethal form of stomach

Memorial Sloan Kettering researchers have found a naturally occurring compound that can destroy cancer cells in mice by targeting MYC, a cancer-causing gene that has remained elusive until now.

… Monday, July 28, 2014 Summary Memorial Sloan Kettering researchers have found a naturally occurring compound that can destroy cancer cells in mice by targeting MYC , a cancer-causing gene that has remained elusive until now. Many of the most effective cancer therapies available today have been developed

Researchers learn how prostate cancer cells change their type to survive treatment.

… Friday, September 2, 2022 Cancer cells are adept at developing ways to evade treatments. For example, prostate cancer prostate cancer becomes resistant to hormone therapy hormone therapy by changing a protein called the androgen receptor (AR), which plays a key role in determining cellular identity.

By identifying mutations found in a person’s cancer, this blood test can help doctors tailor treatments to those most likely to benefit.

… Monday, March 23, 2020 Summary In a study published March 23 , scientists at Memorial Sloan Kettering reported that a blood test called a liquid biopsy can identify mutations responsible for resistance to a new class of drugs called PI3K inhibitors. These medicines were recently approved for treating

Scientists have uncovered new information about what orchestrates the complex balance between blood stem cells and mature blood cells, a relationship that is often disrupted in leukemia. The results will lead to a better understanding of the behavior of leukemic cells and may have vital clinical applications for patients recovering from chemotherapy, radiation therapy, or bone marrow transplantation.

… Monday, March 13, 2006 The below press release is from Cancer Cell and is for a study published in the March issue of Cancer Cell. Scientists have uncovered new information about what orchestrates the complex balance between blood stem cells and mature blood cells, a relationship that is often disrupted

… Thursday, March 9, 2023 Update:  On November 27, 2023, the U.S. Food and Drug Administration approved nirogacestat (Ogsiveo™) for adults with desmoid tumors that cannot be treated with surgery alone. The approval was based on research led by investigators at Memorial Sloan Kettering Cancer Center. Nirogacestat

Medical oncologist Mark Kris discusses how new guidelines for preventing nausea and vomiting due to treatment can improve quality of life for people with cancer.

… Monday, July 31, 2017 Summary Medical oncologist Mark Kris discusses how new guidelines for preventing nausea and vomiting due to treatment can improve quality of life for people with cancer. Dr. Kris co-chaired a panel that is releasing the guidelines. The American Society of Clinical Oncology (ASCO